Clinical trials: Peritoneal Carcinomatosis
Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
Paclitaxel for the Treatment of Gastric or Gastroesophageal Cancer
This phase I trial studies the side effects and best dose of paclitaxel for the treatment of gastric or gastroesophageal cancer.
- Conditions
- Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8
- Trial name
- NCT04220827
- Testing
- Paclitaxel
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- M.D. Anderson Cancer Center
Ovarian Cancer
Imatinib Mesylate in Combination With Docetaxel for Advanced, Platinum-Refractory Ovarian Cancer
Imatinib mesylate is an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF), c-Kit, and inhibits PDGF- and SCF-mediated cellular events.
- Trial name
- NCT00216112
- Testing
- Imatinib Mesylate, Docetaxel
- Where
- 9 sites in United States
- Volunteers
- 23 people
- Sponsor
- Daniela Matei, MD
Colo-rectal Cancer
Performance of Spectral CT-scan in Patients With Metastatic Colorectal Cancer: a Prospective Multicentre Study
Spectral CT is a rapidly expanding imaging modality that allows a reduction in iodine dose and irradiation compared to conventional scanning.
- Trial name
- NCT06024837
- Testing
- CT Images
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Secondary Peritoneal Cancers, Colorectal Cancer
PITCHER (Peritoneal Carcinomatosis Heterogeneity)
How epigenetic deregulation affects gene expression patterns in subclones of the same tumor is poorly known. Peritoneal Carcinomatosis (PC) is a condition in which multiple metastases of the same abdominal tumor develop in the…
- Conditions
- Secondary Peritoneal Cancers, Colorectal Cancer, Ovarian Cancer
- Trial name
- NCT04714957
- Testing
- construction of a database of genetic and epigenetic data on peritoneal carcinomatosis of colorectal or ovarian origin.
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Hospices Civils de Lyon
Stomach Neoplasms, Colorectal Neoplasms
Surgery Plus Intraoperative Peritoneal Hyperthermic Chemotherapy (IPHC) to Treat Peritoneal Carcinomatosis
OBJECTIVES: Determine response and survival of patients with peritoneal carcinomatosis treated with cytoreductive surgery plus intraoperative peritoneal hyperthermic chemotherapy with cisplatin and mitomycin Assess the quality of…
- Conditions
- Stomach Neoplasms, Colorectal Neoplasms, Neoplasm Metastasis, Mesothelioma
- Trial name
- IPHC (NCT00454519)
- Testing
- cytoreductive surgery, intraoperative peritoneal hyperthermic chemotherapy with cisplatin and mitomycin
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Wuhan University
Malignant Ascites, Colorectal Adenocarcinoma
TLR9 Immunotherapy for Peritoneal Carcinomatosis
The goal of this clinical trial is to determine the safety and efficacy of of ACM-CpG for inoperable peritoneal metastases or malignant ascites.
- Conditions
- Malignant Ascites, Colorectal Adenocarcinoma, Peritoneal (Metastatic) Cancer, Appendiceal Adenocarcinoma
- Trial name
- TIPC (NCT07658196)
- Testing
- ACM-CpG
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Brown University
Peritoneal Carcinomatosis
Intraperitoneal Docetaxel in Combination With mFOLFOX6 for Gastric Cancer Patients With Peritoneal Carcinomatosis
This is a single-center, open-label, non-randomized, uncontrolled Phase 1 study of intraperitoneal docetaxel in combination with systemic mFOLFOX6 for patients who have gastric cancer with gross peritoneal carcinomatosis (GC-PC).
- Trial name
- NCT04583488
- Testing
- Intraperitoneal docetaxel
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Johns Hopkins University
Colorectal Cancer, Colorectal Neoplasms
Feasibility Study of a 4 Stage Bowel Obstruction Cancer Diet
Bowel obstruction is a common complication in patients with ovarian, peritoneal and bowel cancer due to a mass or spread of disease, causing narrowing to the gut, as these cancers can grow on the bowel surface.
- Conditions
- Colorectal Cancer, Colorectal Neoplasms, Colorectal Carcinoma, Colorectal Adenocarcinoma
- Trial name
- BOUNCED (NCT04898842)
- Testing
- Dietary intervention
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- Royal Surrey County Hospital NHS Foundation Trust
Colorectal Cancer
A Study of the Safety and Biological Activity of Intraperitoneal (IP) EGEN-001 Administered Alone and in Combination With Standard Chemotherapy in Colorectal Peritoneal Carcinomatosis Patients
Colorectal cancer may be caused by a build-up of genetic defects, or damaged genes within the body's cells. When genes are damaged, the body may be unable to produce a group of proteins, called cytokines, used by the immune…
- Trial name
- NCT01300858
- Testing
- EGEN-001-301
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- EGEN, Inc.
Ovarian Cancer
Phase 2 Study of JX-594 in Patients With Peritoneal Carcinomatosis of Ovarian Cancer Origin
This is a single-arm open-label Phase 2 study in patients with peritoneal carcinomatosis of ovarian origin that are not eligible for curative treatments.
- Trial name
- NCT02017678
- Testing
- JX-594
- Where
- Canada
- Sponsor
- Andrea McCart
Gastric Cancer, Peritoneal Carcinomatosis
Randomized Controlled Trial to Prevent Peritoneal Seeding in Gastric Cancer
Randomized Controlled Trial to Prevent Peritoneal Seeding in Gastric Cancer
- Trial name
- HIPECStomach (NCT01683864)
- Testing
- positive cytology with HIPEC
- Where
- Germany
- Volunteers
- 3 people
- Sponsor
- University Hospital Tuebingen
Colorectal Cancer, Peritoneal Carcinomatosis
Near-Infrared Imaging of Peritoneal Carcinomatosis From Colorectal Cancer
The purpose of this study is to determine if Near-Infrared fluorescence imaging is an effective approach to detect the colorectal tumoral tissues and peritoneal implants in colorectal cancer patients.
- Trial name
- OC-AP-ICG-IV (NCT02032485)
- Testing
- Indocyanine Green
- Where
- Belgium
- Volunteers
- 10 people
- Sponsor
- Jules Bordet Institute
Ovarian Cancer
Study of the Isotopic Distribution of Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis of Ovarian Origin
The treatment of advanced ovarian cancer is based on the combination of chemotherapy based on platinum salt and surgery whose quality is the major prognostic factor.
- Trial name
- ISOTOVE (NCT02667925)
- Testing
- Intraperitoneal cisplatin with nanocis
- Where
- France
- Sponsor
- Centre Jean Perrin
Peritoneal Carcinomatosis
PIPAC With Nab-paclitaxel and Cisplatin in Peritoneal Carcinomatosis
Phase Ib trial including investigating the combination of nab-paclitaxel and cisplatin in patients diagnosed with peritoneal carcinomatosis related to pancreatic, oeso-gastric, ovarian cancer or primitive peritoneal mesothelioma.
- Trial name
- Nab-PIPAC (NCT04000906)
- Testing
- Nab paclitaxel, Cisplatin
- Where
- 2 sites in Switzerland
- Volunteers
- 18 people
- Sponsor
- University Hospital, Geneva
Colorectal Peritoneal Carcinomatosis
Cytoreduction and Intraperitoneal Chemotherapy Versus Systemic Chemotherapy in Colorectal Peritoneal Carcinomatosis
The purpose of this study is to see if there is a difference in survival between two different treatment strategies for colorectal peritoneal surface disease.
- Trial name
- NCT01524094
- Testing
- Systemic chemotherapy alone (oxaliplatin, 5-fluorouracil, isovorin), Cytoreductive surgery (CRS) plus postoperative intraperitoneal chemotherapy (5-fluorouracil, isovorin)
- Where
- Sweden
- Volunteers
- 49 people
- Sponsor
- Uppsala University
Stomach Neoplasm, Peritoneal Carcinomatosis
Gastrectomy + Cytoreductive Surgery + HIPEC for Gastric Cancer With Peritoneal Dissemination.
A randomized controlled two-armed phase III trial for gastric cancer patients with peritoneal dissemination. Randomization between gastrectomy + cytoreductive surgery + HIPEC (experimental arm) and palliative systemic…
- Trial name
- PERISCOPEII (NCT03348150)
- Testing
- Cytoreductive surgery + Gastrecomy, Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
- Where
- Netherlands
- Volunteers
- 102 people
- Sponsor
- The Netherlands Cancer Institute
Gastrointestinal Neoplasm
Debulking and Chemotherapy With or Without Intraperitoneal Chemotherapy to Treat Peritoneal Carcinomatosis
This study will determine which of the two following treatment regimens provides greater benefit to patients with peritoneal carcinomatosis (gastrointestinal cancer that has spread throughout the abdomen): Surgical removal of…
- Trial name
- NCT00052962
- Testing
- Cytoreductive surgery, Continuous hyperthermic peritoneal perfusion (HIPEC/CHPP)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Peritoneal Carcinomatosis, Colon Cancer
Clinical Trial on HIPEC With Mitomycin C in Colon Cancer Peritoneal Metastases (GECOP-MMC)
The aim of this study is to assess whether there are differences in PERITONEAL RECURRENCE in patients with Colon Cancer Peritoneal Metastases treated with complete surgical resection and systemic chemotherapy, with (Group 1) or…
- Trial name
- GECOP-MMC (NCT05250648)
- Testing
- complete cytoreductive surgery plus HIPEC with Mytomicin C for 90 minutes, complete cytoreductive surgery without HIPEC
- Where
- 31 sites in Spain
- Volunteers
- 216 people
- Sponsor
- Hospital Universitario de Fuenlabrada
Pancreatic Cancer, Thyroid Cancer
Integrated Cancer Repository for Cancer Research
The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer…
- Conditions
- Pancreatic Cancer, Thyroid Cancer, Lung Cancer, Esophageal Cancer
- Trial name
- iCaRe2 (NCT02012699)
- Where
- 42 sites in United States
- Volunteers
- 999,999 people, healthy volunteers welcome
- Sponsor
- University of Nebraska
Fallopian Tube Cancer, Metastatic Cancer
SCH-58500 in Treating Patients With Primary Ovarian, Fallopian Tube, or Peritoneal Cancer (C95084)
RATIONALE: Giving the p53 gene for ovarian, fallopian tube, or peritoneal cancer may inhibit tumor growth. Giving the gene directly into the peritoneum may kill more cancer cells.
- Conditions
- Fallopian Tube Cancer, Metastatic Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00002960
- Testing
- recombinant adenovirus-p53 SCH-58500
- Volunteers
- 59 people
- Sponsor
- Merck Sharp & Dohme LLC